"We’re dismantling some of our tattered safety net and risking the lives of fellow Americans." Worth the read. Gift article #medsky #Medicaid impacts of #bigbeautifulbill www.nytimes.com/2026/01/03/o...

JAMA Most views articles of 2025. #MEDSKY bit.ly/3KZh7CK

🚨HER2CLIMB05 🚨 🔹Pts HER2+ MBC s/p THP x 4-8 cycles ➡️ HP + tucatinib vs HP 🔹PFS 24.9m vs 16.3m p<.0001 🔹HR- 24.9m vs 12.6m 🔹HR+ 25m vs 18m ⚠️ Increase in diarrhea and hepatic AEs 🔹Control arm had inferior PFS when compared to DB-09 control arm #SABCS25 #bcsm

📣lidERA trial📣 🔸Pts with HR+ eBC high/medium risk ➡️ giredestrant vs SOC ET x 5 years 🔸At 32 m, iDFS events 6.7% vs 9.4%, HR 0.7, p=.0014 🔸Arthralgias similar 📍1st trial to report benefit of SERD in the adjuvant tx 📋Looking forward to further data & other trials including CDK4/6i & SERDs💊 #SABCS25

Good morning ☀️ Your Day 2 research recap from the San Antonio Breast Cancer Symposium is here! Check out the highlights now: https://bit.ly/SABCS25 #SABCS25 #breastcancerresearch #BreastCancerNews #BreastCancer #breastcancerawareness

LBCA was proud to sponsor the special session on lobular breast cancer at SABCS! #ILC #ILCawareness #lobularbreastcancer #SABCS25

A new, highly sensitive liquid biopsy test may better detect minimal residual disease (MRD) — tiny traces of cancer left after treatment. This could one day help identify who is at higher risk of recurrence and who may safely skip extra therapy. Learn more: https://bit.ly/SABCS25 #SABCS25 #bcsm

New data presented at #SABCS25 shows that adding a breast MRI to a diagnostic mammogram does not improve five-year recurrence rates for patients with stage I/II HR negative breast cancer. spr.ly/63320C8iqk#SABCS25#OncSky #EndCancer

At #SABCS25, new HER2CLIMB-05 results showed Tukysa + Herceptin + Perjeta helped people live longer without their metastatic #breastcancer progressing — 25 months vs. 16. 💊 Because Tukysa is taken orally, this combo may also be easier for many people to manage. Learn more: https://bit.ly/SABCS25

Now at #SABCS25! GS1-03 Matteo Lambertini is presenting an exploratory analysis of #ALTTO trial: Adjuvant Aromatase Inhibitor or Tamoxifen in patients with HR-positive/HER2-positive Early Breast Cancer.

Want to see the lasted posts from #ASH25 or #SABCS25 check out the conference feed! #cansky #oncsky #medsky

#ASH25 #bmtsm Amin: effect of donor age (>/< 30) with MUD PTCY alloHCT.

#ASH25 #bmtsm Amin: with N=1227 <30, 670 >30yo, no apparent difference in RFS/OS, NRM, and most GVHD outcomes. Incr aGVHD 3-4 w older donors but did not affect survival. Sensitivity analyses showed no age cutoff distinguished outcomes.

#ASH25 (Abs 47): Encouraging early results (N=21, median age 70 y) from ph2 SAVE trial of all-oral regimen: revumenib + decitabine/cedazuridine + venetoclax in ND NPM1- or KMT2A-mutated AML. 86% ORR, 81% CR/CRh. #Medsky #cansky #oncsky #AML www.cancercommunicator.com/oral-menin-b...

Covering #ASH25 from home this year! Glad to have this as an option but miss being onsite.

Symptom-based PFS CLL/SLL #ASH25 - 606 pts in ALPINE (zanu v ibru) - longitudinal fatigue, insomnia, N/V associated with increased risk of PD (regardless of BTKi) - zanu: lower odds of symptom worsening vs ibrutinib More trial data demonstrating prognostic value of PROs! #leusm #lymsm

Backdoor privatization of Medicare “When third-party entities are paid based on the volume of denied services, there is a clear risk that care that is medically necessary for certain patients will be inappropriately denied in pursuit of savings" www.kuow.org/stories/thou... #medsky #medicare

"Nvidia and AMD and...Hewlett Packard Enterprise and Dell have already agreed to build facilities within the national labs...Some data will be shared with AI companies but...the government would withhold sensitive information that could put national security at risk" nyti.ms/3XR2uUG

Welcome to the Science feed! Please read our FAQs for instructions for how to be added as a contributor: bossett.io/science-feed/ Mod introductory posts linked below⬇️ Use the test tube emoji on posts you want to appear in the feed🧪 Please like the feed and make sure you follow our feed rules:

#ESMO25: Peri-operative enfortumab vedotin plus pembrolizumab significantly prolonged event-free and overall survival in cisplatin-ineligible patients with muscle-invasive #BladderCancer in the phase III KEYNOTE-905/EV-303 trial #ESMODailyReporter➡️https://ow.ly/YVy550XeuKH#ESMO25#BladderCancer

Lots of exciting data at #ESMO25. Here are the 3 Presidential Symposia presentations. Tomorrow: DESTINY-Breast11 (high-risk HER2+ eBC), DESTINY-Breast05 (high-risk HER2+), KEYNOTE-05 (MIBC), KEYNOTE-B96 (ovarian). #BCSM #Bladdercancer #gusm #ovariancancer #gynsm

The addition of local consolidative therapy to osimertinib improved PFS vs osimertinib alone in patients with EGFR-mutated locally advanced or metastatic #NSCLC (LBA72) NorthStar teial #ESMO25 bit.ly/4qnGuht #lcsm

At #ESMO25, explore how AI & digital tools are shaping oncology: 📌 AI-based image biomarkers 📌 Clinical trials in the age of AI 📌 Digital tools for off-site care 📌 ChatGPT & cancer care 📅 17–19 Oct

It’s here! #ESMO25 kicks off today — Packed agenda with important data, some practice changing. Check out studies that will presented in the 3 Presidential Symposia 👇

Top 10 Breast Cancer Abstracts at ESMO25 - Suggested by Paolo Tarantino @ptarantinomd.bsky.social oncodaily.com/voices/esmo2... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #BreastCancer #ESMO25

“We have a tendency to try to find a one-size-fits-all answer, and hormone therapy is one of the best examples of where one-size-fits-all answers do not work and lead to harmful decision making” @jama.com bit.ly/4mO0Qxr #medsky #womenshealth #menopause

Functional high-risk (FHR) myeloma (relapse< 18 months) is an unmet medical need in MM. Katja Weisel, MD, spoke about how patients at FHR may be identified and encouraged CAR-T consideration for FHR patients at first relapse. #IMS25

What’s behind the rise in GI cancers among young adults? Dr Marshall explores this in our latest #OncologyUnscripted. 🎥 Watch here: clinicalcaresolutions.net/activities/o... #GIcancer #CancerCare #MedSky #OncSky #CanSky #CRC

Final OS from FLAURA2 at #WCLC25: osimertinib + chemo vs osimertinib alone in untreated advanced EGFR-mutated NSCLC. 👉 Median OS: 47.5 vs 37.6 mo (HR 0.77; p=0.02) 👉 3-yr OS: 63% vs 51% www.cancercommunicator.com/post/wclc25-... #LungCancer #NSCLC #Oncology #LCSM #CanSky #OncSky #MedSky

At #WCLC25 results of #FLAURA2 showed a 47.5 mo mOS w/ osimertinib+chemo in pts w/ advanced EGFRm+ NSCLC vs 37.6 with osi monotherapy. Benefit seen across subgroups. Longer chemo-free period with combo. #LCSM #LungCancer #NSCLC #oncsky #cansky

MARIPOSA phase 3 trial: In advanced non–small-cell lung cancer with EGFR mutations, amivantamab–lazertinib led to longer overall survival than osimertinib but was associated with an increased risk of adverse events of grade 3 or higher. nej.md/4p6j53k #WCLC25 | @iaslc.bsky.social

📢 Introducing Cancer Conference Hub Follow real-time updates from the world’s leading hematology and oncology meetings — ASCO, ESMO, ASH, EHA, WCLC, SOHO, SABCS, AACR, and more. 👉 Explore the hub here: bsky.app/profile/did:...

Catch the latest updates from #WCLC25 — clinical data, expert insights, and practice-changing news, all in one place. 👉 Follow the curated feed here: Cancer Communicator | WCLC25 #LCSM #LungCancer #NSCLC #SCLC #CancerNews #Oncsky #Medsky #Cansky

There are so many medical conferences held in Florida including this year's @ash.hematology.org annual meeting. Should we stop holding medical conferences in Florida? If they don't follow the evidence, why should the evidence be presented there? #medsky www.nytimes.com/2025/09/03/u...

"Independent rural hospitals are increasingly joining what are called clinically integrated networks, collaborative groups that allow them to avoid selling out to larger health systems while sharing resources to save money and improve patient care" #medsky #hospitalhealth www.npr.org/sections/sho...

While I don't disagree with the majority of this, I think the models, even if they stay exactly as they are (which the won't), will be sufficiently disruptive to our everyday lives-once organizations figure out how to use them to save $$ (which they haven't) www.nytimes.com/2025/09/03/o... #AI

WA, OR, and CA health alliance formed recognizing the importance of independent science and medicine. It's unfathomable what has happened at one of our most revered institutions. www.nytimes.com/2025/09/03/u... #medsky #cdc

"Patients initiating semaglutide or tirzepatide had a more than 40% lower risk of hospitalization for heart failure or all-cause mortality compared with sitagliptin...In a head-to-head comparison, tirzepatide showed no meaningful benefit over semaglutide." #medsky #obesitymedicine bit.ly/41xqRcq

"Health care is exceptional among U.S. markets in that profits and value often don’t align...When quality is hard to assess, market power is sizable, and patients are vulnerable, corporatization carries the risk of increasing prices or reducing quality." #medsky www.nejm.org/doi/full/10....

At a dr appt, I was asked permission to use an AI app to take notes. I was told the app would record, write up notes, and delete the recording. Thoughts on this, Especially with otterai class actuin lawsuit? Should we be signing informed consent? #MedSky #AIinHealthcare #HealthTech #DigitalHealth

"since the widespread adoption of generative AI, early-career workers (ages 22-25) in the most AI-exposed occupations have experienced a 13 percent relative decline in employment even after controlling for firm-level shocks." digitaleconomy.stanford.edu/wp-content/u...

$491 BILLION from MediCARE for an already fragile healthcare system "The CBO estimates that Medicare, the federal health insurance program for Americans over age 65, could potentially see as much as $491 billion from 2027 to 2034 if Congress does not act." #medsky abcnews.go.com/US/wireStory...

Large but retrospective study. People that get Zoster after C19 are at risk of other serious illnesses over the three year follow-up. www.nature.com/articles/s41...

The order “ends up disrupting a decades-long and very productive partnership or collaboration between the federal government and the research institutions” by making federal agencies less reliable funders #medsky #academicsky www.statnews.com/2025/08/08/t... via @statnews.com

It’s mind boggling how many additional people this administration is killing. “I have been in this business for over 50 years on the front lines of public health…And I can say unequivocally that this was the most dangerous public health decision I have ever seen made by a government body.”

Those companies want these data so badly. Highly recommend reading reading Empire of AI by @karenhao.bsky.social

Alarm bells!!! "The administration is working with some of the largest American companies on the record-keeping system, including Google, Amazon, Apple and OpenAI. The Centers for Medicare and Medicaid Services will oversee the effort." #medsky #cansky www.nytimes.com/2025/07/30/u...

Hundreds of millions of dollars suspended for cancer, diabetes, and Alzheimer's research (among many, many other equally important diseases and endeavors) and for what? What is the point of all of this? Help me understand how this makes our country better, stronger, and healthier in any way.

ODAC voted against the overall benefit-risk of belantamab mafodotin combinations (BVd and BPd) not disputing the drug's efficacy, but citing toxicity and a missed opportunity to optimize dose along with inadequate enrollment of the US population. #MMSM #FDA www.youtube.com/live/CLhBI3U...